Development
Biogen Inc.
BIIB
$138.60
$3.662.71%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 2.39B | 2.53B | 2.48B | 2.48B | 2.54B |
| Total Other Revenue | -- | -- | -20.70M | -18.90M | 639.50M |
| Total Revenue | 2.39B | 2.53B | 2.46B | 2.46B | 2.54B |
| Cost of Revenue | 618.30M | 659.60M | 1.18B | 1.23B | 570.90M |
| Gross Profit | 1.77B | 1.87B | 1.28B | 1.23B | 1.97B |
| SG&A Expenses | 608.10M | 752.70M | 536.50M | 605.00M | 638.20M |
| Depreciation & Amortization | 76.60M | 60.90M | 52.90M | 50.20M | 55.40M |
| Other Operating Expenses | 54.30M | 50.50M | 56.90M | 57.10M | 35.20M |
| Total Operating Expenses | 1.93B | 2.26B | 1.82B | 1.95B | 1.90B |
| Operating Income | 461.10M | 270.50M | 633.30M | 517.30M | 645.10M |
| Income Before Tax | 291.60M | -141.20M | 708.10M | 438.30M | 603.80M |
| Income Tax Expenses | 42.70M | -72.90M | 114.80M | 50.70M | 54.30M |
| Earnings from Continuing Operations | 248.90M | -68.30M | 593.30M | 387.60M | 549.50M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 800.00K | 200.00K | -1.70M | 300.00K | 900.00K |
| Net Income | 249.70M | -68.10M | 591.60M | 387.90M | 550.40M |
| EBIT | 461.10M | 270.50M | 633.30M | 517.30M | 645.10M |
| EBITDA | 601.20M | 395.50M | 750.70M | 629.60M | 764.90M |
| EPS Basic | 1.72 | -0.47 | 4.09 | 2.69 | 3.82 |
| Normalized Basic EPS | 1.72 | 1.24 | 2.79 | 2.28 | 2.88 |
| EPS Diluted | 1.71 | -0.47 | 4.07 | 2.67 | 3.80 |
| Normalized Diluted EPS | 1.71 | 1.24 | 2.78 | 2.26 | 2.85 |
| Average Basic Shares Outstanding | 144.90M | 144.80M | 144.70M | 144.40M | 144.10M |
| Average Diluted Shares Outstanding | 145.70M | 144.80M | 145.50M | 145.20M | 145.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |